Full-Time

Associate Director

LNP Development

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

No salary listed

Expert

Cambridge, MA, USA

Hybrid environment with sufficient on-site presence.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MS in Pharmaceutical Sciences, Chemical engineering, Bioengineering or related field with of drug product and CMC development experience (PhD or MS with 12+ years of relevant experience)
  • Deep understanding of late-stage product development activities
  • Experience with PPQ and late-stage robustness activities is preferred
  • Experienced in building the CMC dossier for regulatory submissions within the development section as an author/reviewer
  • Strong knowledge of regulatory requirements
  • Strong interpersonal skills and the ability and interest to serve as a team member/leader in an environment where individual initiative, collaboration, and accountability are valued
  • Excellent computational, written, and verbal communication skills
  • Strong organizational abilities
  • Ability to work with a diverse group of scientists and engineers
  • Ability to travel and support workstreams in the US and internationally
  • Ability to work in a hybrid environment with sufficient on-site presence
Responsibilities
  • Contributes to the Chemistry, Manufacturing and Controls (CMC) strategy
  • Engages in scientific and technical discussions with multi-disciplinary team members to move programs into late-stage development
  • Uses knowledge and expertise of statistics to collaborate on Drug Product Development: Quality by Design, formulation development and optimization, process design and optimization, scale-up, determining manufacturing design spaces, validation, experimental and registrational stability studies, probabilistic assessment of risk for critical quality attributes
  • Acts as a technical point of contact, or SME within the group as well as other departments; trains others
  • Leads technology transfer projects, including the establishment of the process/parameters for each unit operation of the process, and up until the completion of process performance qualification and subsequent CMC filing activities
  • Develops and maintains effective working relationships with other division groups in support of technology transfer, validation, and product development activities
  • As part of support for GMP manufacturing activities, assists with relevant investigations and CAPAs
  • Generate data and knowledge for regulatory filings through planning and execution of experimental plans with minimal supervision, within project timelines
  • Authors and supports preparation of regulatory documents
Desired Qualifications
  • Experience with PPQ and late-stage robustness activities is preferred

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by emphasizing a values-driven approach, a strong team of experts, and a commitment to rigorous scientific development. The ultimate goal of the company is to advance genetic medicine to improve the lives of patients suffering from genetic disorders.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Beam raised $500 million to advance its R&D and expand its genetic medicine pipeline.
  • Successful Phase 1/2 trial for BEAM-302 shows potential beyond sickle cell disease.
  • Partnership with Eli Lilly highlights commercial potential and industry confidence in Beam's technology.

What critics are saying

  • Increased competition from CRISPR Therapeutics could impact Beam's market share.
  • New CFO appointment may lead to transitional challenges or shifts in financial strategy.
  • $500 million equity offering may dilute existing shareholders' value, causing dissatisfaction.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a safer alternative to traditional CRISPR methods.
  • The company focuses on lifelong cures for genetic disorders, not just symptom management.
  • Beam's technology targets single base changes without causing double-stranded DNA breaks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
GlobeNewswire
Mar 10th, 2025
Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Benzinga
Mar 10th, 2025
Beam Therapeutics Reports Data, Raises $500M

Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.

GlobeNewswire
Dec 6th, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.

CityBiz
Jul 15th, 2024
Beam Therapeutics Chief Financial Officer Terry-Ann Burrell to Retire

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.

Securities.io
May 21st, 2024
10 Rare Diseases Specialist Stocks

Rare Diseases – Curing The IncurableWhile not entirely solved, a lot of major deadly illnesses that have plagued humanity have become more manageable over the last century, from bacterial (antibiotics) and viral (vaccines) infections to diabetes (insulin).There is, however, a wide array of rare diseases which are still mostly incurable. Most of the time, this is because these diseases are not caused by an external threat, but by a biological dysfunction inside the very cells of the patient. This is quickly changing, thanks to progress in biosciences.On one hand, with the human genome sequenced and much more advanced analytical methods, scientists can finally understand what are the root causes of rare diseases. Even AI is now helping interpret the data and provide new insights .On the other hand, new technologies like gene editing open the possibility of fixing deficient cells or organs, restoring normal function.Rare diseases each affect less than 1 in 2,000 people, with more than 6000 different rare diseases. Despite their individual rarity, together, they affect around 4% of the population, with as many as 30 million people in just Europe .3/4 of rare diseases affect children, 72% are genetic in origin, and it takes on average 5 years for rare disease patients to get a diagnosis.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize .What sets CRISPR Therapeutics apart is the all-star team of founders, including Dr